Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

nContact Surgical Inc.

This article was originally published in Start Up

Executive Summary

nContact Surgical Inc. aims to merge the best of surgical and interventional techniques to provide a truly minimally invasive, single procedure solution for atrial fibrillation patients. Its Numeris Coagulation system with VisiTrax is used in the surgical portion of the procedure, in which VisiTrax integrates suction, perfusion and radiofrequency energy to create long linear lesions on the outside of a beating heart. The electrophysiologist then uses a catheter to complete the biatrial lesion pattern inside the heart.

You may also be interested in...



Financings Of The Fortnight: Corporate Venture Is Here To Stay

Private funding rounds involving corporate venture tend to be much richer in the biotech arena, a recent review indicates.

Start-Up Previews (06/2010)

A preview of the emerging health care companies profiled in the current issue of Start-Up. "Altering The Insulin Resistance System" features profiles of Catabasis Pharmaceuticals, Limerick BioPharma, Marcadia BIotech and Rhythm Pharmaceuticals. Plus these Start-Ups Across Health Care: nContact Surgical, NormOxys and Thermopeutix.

CSL’s Hemgenix Gene Therapy Does Not Need A REMS, FDA Tells National Hemophilia Foundation

Peter Marks says labeling for CSL’s hemophilia B treatment adequately conveys its risks. He also denies NHF request that the label cite eligibility criteria used in clinical trials, responding to a citizen petition on the day the agency approves the therapy.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT037676

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel